Company Encyclopedia
View More
name
Pharscin Pharma
002907.SZ
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases.
3.120 T
002907.SZMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking129/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.46%C
    • Profit Margin9.49%B
    • Gross Margin57.10%B
  • Growth ScoreC
    • Revenue YoY-0.51%D
    • Net Profit YoY19.37%B
    • Total Assets YoY4.50%C
    • Net Assets YoY3.18%C
  • Cash ScoreC
    • Cash Flow Margin1054.17%B
    • OCF YoY-0.51%D
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreA
    • Gearing Ratio14.40%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pharscin Pharma: Injectable Sulbactam-Nafcillin has received drug re-registration approval

    Pharscin Pharma announced that it recently received the "Drug Re-registration Approval Notice" for its product, injectable sulbactam-natamycin, issued by the Chongqing Municipal Drug Administration. The drug approval number is valid until October 22, 2030. The re-registration of this product is approved. Since this product has not been produced for a long time, before resuming production, the holder must complete the relevant work according to the requirements of related documents and submit a resumption application to the Municipal Drug Administration. After on-site inspection and passing the quality check of a batch of products, and subsequent two batches of products passing inspection, it can be marketed for sale

    Zhitong·
    SZ
    002907
    +0.91%
    Zhitong·
    SZ
    002907
    +0.91%

    Pharscin Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 72.4556 million yuan, a year-on-year decrease of 2.84%

    According to the Zhitong Finance APP, Pharscin Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 626 million yuan, a year-on-year increase of 1.90%. The net profit attributable to shareholders of the listed company was 72.4556 million yuan, a year-on-year decrease of 2.84%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 52.2035 million yuan, a year-on-year decrease of 13.03%

    Zhitong·
    SZ
    002907
    +0.91%
    Zhitong·
    SZ
    002907
    +0.91%

    Pharscin Pharma: Crizotinib capsules are expected to be launched for sale by the end of next year

    Pharscin Pharma responded on the interactive platform on October 23rd, stating that Crizotinib capsules are currently under the patent protection period of the original research company, and they are expected to be available for sale by the end of next year. The sales of the drug are influenced by various factors including industry policies, and the company is currently unable to estimate sales figures

    Zhitong·
    SZ
    002907
    +0.91%
    Zhitong·
    SZ
    002907
    +0.91%

    Pharscin Pharma obtained the drug registration certificate for Crizotinib capsules

    Pharscin Pharma has obtained the drug registration certificate for Crizotinib capsules issued by the National Medical Products Administration. This drug was launched in the Chinese market in 2013 and was included in the medical insurance system in 2018, with over ten years of clinical application experience, primarily used for the treatment of patients with advanced non-small cell lung cancer who are ALK-positive and ROS1-positive

    Zhitong·
    SZ
    002907
    +0.91%
    Zhitong·
    SZ
    002907
    +0.91%

    Pharscin Pharma's controlling shareholder's concerted action parties plan to reduce their holdings by no more than 3%

    According to the Zhitong Finance APP, Pharscin Pharma announced that the company recently received a notice from Mr. You Hongtao, a concerted actor of the controlling shareholder, and Shanghai Tiancheng Investment Management Co., Ltd. - Tiancheng Tianli No. 1 Private Securities Investment Fund (referred to as "Tiancheng Tianli No. 1 Fund") regarding the plan to reduce their holdings in the company. The total reduction plan will not exceed 12.5278 million shares, accounting for no more than 3% of the company's total share capital

    Zhitong·
    SZ
    002907
    +0.91%
    Zhitong·
    SZ
    002907
    +0.91%
    © 2025 Longbridge｜Disclaimer